Recombinant Human Versican Isoform V3 His-tag Protein, CF

Catalog #: 3054-VN Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
3054-VN-050

Recombinant Human Versican Isoform V3 His-tag Protein Binding Activity

2 Images

Product Details

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human Versican Isoform V3 His-tag Protein, CF Summary

Product Specifications

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA. When Recombinant Human Versican Isoform V3 (Catalog # 3054-VN) is coated at 0.25 μg/mL, 100 μL/well, Biotinylated Hyalurinan binds with an ED₅₀ of 0.25-1.5 ng/mL.

Source

Chinese Hamster Ovary cell line, CHO-derived human Versican protein
Leu21-Tyr646, with a C-terminal 6-His tag

Accession #

P13611-4

N-terminal Sequence
Analysis

Leu21

Predicted Molecular Mass

71 kDa

SDS-PAGE

78-89 kDa, reducing conditions

Product Datasheets

3054-VN

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

3054-VN

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, ≤ -20 °C under sterile conditions after reconstitution.

Scientific Data

Binding Activity

View Larger

When Recombinant Human Versican Isoform V3 (Catalog # 3054-VN) is coated at 0.25 μg/mL, 100 μL/well, Biotinylated Hyalurinan binds with an ED₅₀ of 0.25-1.5 ng/mL.

SDS-PAGE

View Larger

2 μg/lane of Recombinant Human Versican Isoform V3 was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 78-89 kDa and 67-80 kDa, respectively.

Reconstitution Calculator

Background: Versican

Versican (versatile proteoglycan; also known as PG-M, CSPG2, ERVR, GHAP, WGN, WGN1) is a 500-600 kDa, secreted member of the large aggregating chondroitin sulfate proteoglycan family, which includes aggrecan, neurocan, and brevican (1-3). The canonical sequence of human Versican (Isoform V0) is 3396 amino acids (aa) in length. It contains an N-terminal hyaluronan-binding region, two large, alternately spliced GAG attachment domains (GAG alpha and GAG beta), two EGF-like domains, a selectin-like region, and a complement regulatory protein-like domain (2). Human Versican has multiple alternative splice variants that include variations mainly in the GAG regions. This product is the Isoform V3 which includes one mutation at aa 348 (Pro to Arg) and lacks of the entire GAG domains (aa 349-3089) compared to Isoform V0. Versican is known to associate with hyaluronan (4), tenascin (5-7), fibronectin (8), fibulin (9), and CD44 (10) in the extracellular matrix that may contribute to the malignant properties of tumor cells (11). It has an anti-adhesive effect on cells, facilitating tumor migration and invasion (12). The multiple alternative splice variants of human Versican could affect cell-cell and cell-matrix adhesion (13-15), migration (16), proliferation, apoptosis (17), and mesenchymal-epithelial transition (18). The Versican gene is expressed in several different tissues, and it is over-expressed in several cancer types, including prostate (19), brain (20), ovary (21), breast (22) and melanoma (11).

References

Shinomura, T. et al. (1993) J. Biol. Chem. 268:14461.
Zimmermann, D. R. and E.Ruoslahti (1989) EMBO J. 8:2975.
Margolis, R. U. and R. K. Margolis (1994) Methods Enzymol. 245:105.
Lebaron, R. G. et al. (1992) J. Biol. Chem. 267:10003.
Perides, G. et al. (1993) Anat. Embryol. (Berl.) 188:467.
Aspberg, A. et al. (1995) Proc. Natl. Acad. Sci. U.S.A. 92:10590.
Aspberg, A. et al. (1997) Proc. Natl. Acad. Sci. U.S.A. 94:10116.
Braunewell, K. H. et al. (1995) Eur. J. Neurosci. 7:805.
Olin, A. I. et al. (2001) J. Biol. Chem. 276:1253.
Kawashima, H. et al. (2000) J. Biol. Chem. 275:35448.
Touab, M. et al. (2002) Am. J. Pathol. 160:549.
Yamagata, M. et al. (1989) J. Biol. Chem. 264:8012.
Wu, Y. et al. (2002) J. Biol. Chem. 277:12294.
Zheng, P. S. et al. (2004) J. Cell Sci. 117:5887.
Lemire, J. M. et al. (2002) J. Cell Physiol. 190:38.
Mjaatvedt, C.H. et al. (1998) Dev. Biol. 202:56.
Sheng, W. et al. (2005) Mol. Biol. Cell. 16:1330.
Sheng, W. et al. (2006) Mol. Biol. Cell. 17:2009.
Ricciardelli, C. et al. (1998) Clin. Cancer Res. 4:963.
Paulus, W. et al. (1996) J. Neuropathol. Exp. Neurol. 55:528.
Voutilainen, K. et al. (2003) Int. J. Cancer 107:359.
Nara, Y. et al. (1997) Histochem. J. 29:21.

Entrez Gene IDs

1462 (Human); 13003 (Mouse)

Alternate Names

Chondroitin sulfate proteoglycan 2WGN; Chondroitin sulfate proteoglycan core protein 2; CSPG2; CSPG2DKFZp686K06110; ERVR; GHAP; Glial hyaluronate-binding protein; Large fibroblast proteoglycan; PG-M; PG-MWGN1; VCAN; versican core protein; versican proteoglycan; Versican